title: The potential of melatonin in reducing morbidity-mortality after craniocerebral trauma.
abstract: Craniocerebral trauma (CCT) is the most frequent cause of morbidity-mortality as a result of an accident. The probable origins and etiologies are multifactorial and include free radical formation and oxidative stress, the suppression of nonspecific resistance, lymphocytopenia (disorder in the adhesion and activation of cells), opportunistic infections, regional macro and microcirculatory alterations, disruptive sleep-wake cycles and toxicity caused by therapeutic agents. These pathogenic factors contribute to the unfavorable development of clinical symptoms as the disease progresses. Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine endogenously produced in the pineal gland and in other organs and it is protective agent against damage following CCT. Some of the actions of melatonin that support its pharmacological use after CCT include its role as a scavenger of both oxygen and nitrogen-based reactants, stimulation of the activities of a variety of antioxidative enzymes (e.g. superoxide dismutase, glutathione peroxidase, glutathione reductase and catalase), inhibition of pro-inflammatory cytokines and activation-adhesion molecules which consequently reduces lymphocytopenia and infections by opportunistic organisms. The chronobiotic capacity of melatonin may also reset the natural circadian rhythm of sleep and wakefulness. Melatonin reduces the toxicity of the drugs used in the treatment of CCT and increases their efficacy. Finally, melatonin crosses the blood-brain barrier and reduces contusion volume and stabilizes cellular membranes preventing vasospasm and apoptosis of endothelial cells that occurs as a result of CCT.
authors.affiliation: Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, TX, USA, and Center for Rehabilitation and Traumatology of the Hospital University Virgen del Rocio, Seville, Spain. aibar@us.es
authors.forename: M D
authors.initials: MD
authors.lastname: Maldonado
authors.forename: F
authors.initials: F
authors.lastname: Murillo-Cabezas
authors.forename: M P
authors.initials: MP
authors.lastname: Terron
authors.forename: L J
authors.initials: LJ
authors.lastname: Flores
authors.forename: D X
authors.initials: DX
authors.lastname: Tan
authors.forename: L C
authors.initials: LC
authors.lastname: Manchester
authors.forename: R J
authors.initials: RJ
authors.lastname: Reiter
mesh_terms: D006259:Craniocerebral Trauma / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D064420:Drug-Related Side Effects and Adverse Reactions; D016166:Free Radical Scavengers / Q000627:therapeutic use*; D006801:Humans; D008550:Melatonin / Q000627:therapeutic use*; D012893:Sleep Wake Disorders / Q000209:etiology
chemical_list: D016166:Free Radical Scavengers; D008550:Melatonin